Real-time RT-PCR for the determination of topoisomerase II mRNA level in leukaemic cells

Leukemia Research

Volumn 26, Issue 5, 2002, Pages 487-494

  Zhou, Rong ^a   Stolt, Marianne Frostvik ^a   Kronenwett, Ulrike ^a   Gruber, Astrid ^a   Liliemark, Jan ^a   Liliemark, Eva ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Acute myelogenous leukaemia; Chemotherapy; Chronic lymphocytic leukaemia; Drug resistance; Real time RT PCR; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); MESSENGER RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0036210749     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(01)00144-8     Document Type: Article

References (53)

1. Novel mechanisms of drug resistance in leukemia
2. Altered DNA topoisomerase II in multidrug resistance
3. Podophyllotoxins: Current status and recent developments
4. DNA topoisomerase dysfunction: A new goal for antitumor chemotherapy
5. Isolation of cDNA clones encoding the β isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24
6. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22
7. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells
8. Investigating the biological functions of DNA topoisomerases in eukaryotic cells
9. Essential mitotic functions of DNA topoisomerase IIα are not adopted by topoisomerase IIβ in human H69 cells
10. Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells
11. Etoposide targets topoisomerase IIα and IIβ in leukemic cells: Isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique
12. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives
13. Potentiation of etoposide-induced apoptosis by staurosporine in human tumor cells is associated with events downstream of DNA-protein complex formation
14. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
15. Requirements for p-glycoprotein recognition based on structure-activity relationships in the podophyllotoxin series
16. Report of a meeting: Molecular basis of cancer therapy
17. p-glycoprotein expression in patients with acute leukemia-clinical relevance
18. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection
19. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines
20. DNA topoisomerase II isozymes involved in anticancer drug action and resistance
21. Evidence for a critical role of DNA topoisomerase IIα in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line
22. Quantitative determination of mdr1 gene expression in leukaemic cells from patients with acute leukaemia
23. MDR1/p-glycoprotein in haematological neoplasms
24. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia
25. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: Studies of the Southwest Oncology Group Leukemia Research Program
26. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia
27. Competitive reverse transcription-polymerase chain reaction assay for quantification of human multidrug resistance 1 (MDR1) gene expression in fresh leukemic cells
28. MDR1, MRP, topoisomerase IIα/β, and cyclin A gene expression in acute and chronic leukemias
29. Drug resistance mechanisms in chronic lymphocytic leukemia
30. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia
31. mRNA expression of topoisomerase II in human tumors and normal tissues
32. Characterization of topoisomerase IIα gene amplification and deletion in breast cancer
33. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer
34. Topoisomerase IIα expression in breast cancer: Correlation with outcome variables
35. High mdr1- and mrp-, but low topoisomerase IIα-gene expression in B-cell chronic lymphocytic leukaemias
36. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase
37. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization
38. A novel method for real-time quantitative RT-PCR
39. Real-time quantitative PCR
40. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay
41. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR
42. Novel 5′ exonuclease-based real-time PCR assay for the detection of t(14;18)(q32;q21) in patients with follicular lymphoma
43. Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards
44. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes
45. Etoposide-induced DNA strand breaks in relation to p-glycoprotein and topoisomerase II protein expression in leukemic cells from patients with AML and CLL
46. Heterogeneous expression of DNA topoisomerase IIα isoforms in tumor cell lines
47. Topoisomerase IIα expression in acute myeloid leukaemia and its relationship to clinical outcome
48. Mdr1/p-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias
49. Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia
50. Prognostic value of S-phase white blood cell count in B-cell chronic lymphocytic leukemia
51. Topoisomerase II-mediated alterations of K562 drug resistant sublines
52. Etoposide-induced DNA cleavage in human leukemia cells
53. Topoisomerase II expression in normal haemopoietic cells and chronic lymphocytic leukaemia: Drug sensitivity or resistance?